GILEAD SCIENCES Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GILEAD SCIENCES, and when can generic versions of GILEAD SCIENCES drugs launch?
GILEAD SCIENCES has twenty-five approved drugs.
There are ninety-one US patents protecting GILEAD SCIENCES drugs.
There are two thousand four hundred and eleven patent family members on GILEAD SCIENCES drugs in sixty-eight countries and three hundred and seventy-four supplementary protection certificates in nineteen countries.
Summary for GILEAD SCIENCES
| International Patents: | 2411 |
| US Patents: | 91 |
| Tradenames: | 20 |
| Ingredients: | 20 |
| NDAs: | 25 |
| Patent Litigation for GILEAD SCIENCES: | See patent lawsuits for GILEAD SCIENCES |
| PTAB Cases with GILEAD SCIENCES as patent owner: | See PTAB cases with GILEAD SCIENCES as patent owner |
Drugs and US Patents for GILEAD SCIENCES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | 8,822,430*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-002 | Mar 19, 2020 | RX | Yes | No | 8,633,309*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | 8,318,682*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-001 | Oct 10, 2014 | RX | Yes | Yes | 8,889,159*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | 11,007,208*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Gilead Sciences | ATRIPLA | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 021937-001 | Jul 12, 2006 | DISCN | Yes | No | 8,598,185 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-002 | Jun 10, 2021 | RX | Yes | Yes | 11,116,783*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GILEAD SCIENCES
Paragraph IV (Patent) Challenges for GILEAD SCIENCES drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2010-01-26 |
| ➤ Subscribe | Tablets | 200 mg/25 mg/300 mg | ➤ Subscribe | 2015-05-20 |
| ➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2015-12-09 |
| ➤ Subscribe | Tablets | 600 mg/200 mg/300 mg | ➤ Subscribe | 2008-12-29 |
| ➤ Subscribe | Tablets | 150 mg, 200 mg, and 250 mg | ➤ Subscribe | 2012-05-17 |
| ➤ Subscribe | Tablets | 150 mg, 150 mg, 200 mg, 300 mg | ➤ Subscribe | 2018-10-04 |
International Patents for GILEAD SCIENCES Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Serbia | 53691 | ⤷ Subscribe |
| Hong Kong | 1253517 | ⤷ Subscribe |
| New Zealand | 631754 | ⤷ Subscribe |
| Cyprus | 1125089 | ⤷ Subscribe |
| Croatia | P20140379 | ⤷ Subscribe |
| European Patent Office | 2487168 | ⤷ Subscribe |
| Lithuania | 3366295 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for GILEAD SCIENCES Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1663240 | 222 6-2015 | Slovakia | ⤷ Subscribe | PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128 |
| 2822954 | 2018C/031 | Belgium | ⤷ Subscribe | PRODUCT NAME: BICTEGRAVIR OF EEN FARMACEUTISCH ANVAARDBAAR ZOUT HIERVAN, IN HET BIJZONDER NATRIUMBICTEGRAVIR; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| 1663240 | 60/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 2595980 | 53/2020 | Austria | ⤷ Subscribe | PRODUCT NAME: REMDESIVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ESTER DAVON; REGISTRATION NO/DATE: EU/1/20/1459 (MITTEILUNG) 20200703 |
| 2203462 | PA2014040,C2203462 | Lithuania | ⤷ Subscribe | PRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116 |
| 1419152 | C20120012 00058 | Estonia | ⤷ Subscribe | PRODUCT NAME: EVIPLERA - EMTRITSITABIIN/RILPIVIRIIN (HUEDRO-;REG NO/DATE: C(2011)8956 FINAL 28.11.2011 |
| 1564210 | PA2013018,C1564210 | Lithuania | ⤷ Subscribe | PRODUCT NAME: ELVITEGRAVIRUM; REGISTRATION NO/DATE: EU/1/13/830/001, 2013-05-24 EU/1/13/830/002 20130524 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
